Value Propositions

Value Propositions from the August 2014 issue of Value-Based Cancer Care.
Read Article




This collaborative program is based on evidence-based decision support in cancer care, using personalized medicine and realigning payment structure with the goal of increasing patient treatment coordination, improving quality outcomes, and reducing overall costs of cancer care.
Read Article

Researchers at the University of Texas M.D. Anderson Cancer Center have announces a new collaboration with Pfizer to develop immune-based approaches to new therapies for cancer. This new effort is based on M.D. Anderson’s Moon Shots Program that aims to reduce cancer deaths significantly in the future, using the 6 moon shots that target 8 types of difficult-to-treat cancer.
Read Article

Responding to the relentless economic pressures on patients and oncologists and the ever-escalating costs of cancer care delivery, the American Society of Clinical Oncology (ASCO), in collaboration with the Value in Cancer Care Task Force, is developing a working definition of “value” in oncology, as well as identifying how to incorporate the implications of that approach into clinical decision-making in patient care.
Read Article

The National Cancer Institute (NCI) has launched a clinical trial to determine whether selecting therapies based on genetic mutations can improve outcomes in patients with metastatic solid tumors.
Read Article

Empire Genomics, an emerging molecular diagnostics company focused on cancer diagnostics, has recently received approval from the New York State Department of Health for its diagnostic test facility.
Read Article

A new collaborative initiative among Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard has been established to create treatment pathways based on precision (or personalized) medicine for patients with advanced cancer and to try to accelerate the development of personalized therapies.
Read Article

Page 2 of 11